Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck

Min Hee Hong; Chang Gon Kim; Yoon Woo Koh; Eun Chang Choi; Jinna Kim; Sun Och Yoon; Hye Ryun Kim; Byoung Chul Cho

doi:10.1002/hed.24933

Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck

Min Hee Hong, Chang Gon Kim, Yoon Woo Koh, Eun Chang Choi, Jinna Kim, Sun Och Yoon, Hye Ryun Kim, Byoung Chul Cho

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

Background: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m²) on days 1 and 8 plus cisplatin (80 mg/m²) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate. Progression-free survival (PFS), overall survival (OS), and adverse events were also assessed. Results: Between September 2008 and November 2014, 40 patients with recurrent and/or metastatic salivary gland cancer received vinorelbine plus cisplatin chemotherapy. The objective response rate was 35.0%, including 1 complete response. Median PFS and OS rates were 6.3 months and 16.9 months, respectively. No treatment-related deaths occurred. Conclusion: Administering vinorelbine plus cisplatin chemotherapy to patients with recurrent and/or metastatic salivary gland cancers is safe and effective.

Original language	English
Pages (from-to)	55-62
Number of pages	8
Journal	Head and Neck
Volume	40
Issue number	1
DOIs	https://doi.org/10.1002/hed.24933
Publication status	Published - 2018 Jan

Bibliographical note

Funding Information:
This work was supported by a grant from the National Research Foundation (NRF), Republic of Korea (NRF- 2016M3C9A4922809 to Hye Ryun Kim).

Publisher Copyright:
© 2017 Wiley Periodicals, Inc.

All Science Journal Classification (ASJC) codes

Otorhinolaryngology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.24933

Cite this

@article{3a54408b4b2a406eb565cf75c0bf336f,

title = "Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck",

abstract = "Background: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m2) on days 1 and 8 plus cisplatin (80 mg/m2) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate. Progression-free survival (PFS), overall survival (OS), and adverse events were also assessed. Results: Between September 2008 and November 2014, 40 patients with recurrent and/or metastatic salivary gland cancer received vinorelbine plus cisplatin chemotherapy. The objective response rate was 35.0%, including 1 complete response. Median PFS and OS rates were 6.3 months and 16.9 months, respectively. No treatment-related deaths occurred. Conclusion: Administering vinorelbine plus cisplatin chemotherapy to patients with recurrent and/or metastatic salivary gland cancers is safe and effective.",

author = "Hong, {Min Hee} and Kim, {Chang Gon} and Koh, {Yoon Woo} and Choi, {Eun Chang} and Jinna Kim and Yoon, {Sun Och} and Kim, {Hye Ryun} and Cho, {Byoung Chul}",

note = "Funding Information: This work was supported by a grant from the National Research Foundation (NRF), Republic of Korea (NRF- 2016M3C9A4922809 to Hye Ryun Kim). Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2018",

month = jan,

doi = "10.1002/hed.24933",

language = "English",

volume = "40",

pages = "55--62",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck

AU - Hong, Min Hee

AU - Kim, Chang Gon

AU - Koh, Yoon Woo

AU - Choi, Eun Chang

AU - Kim, Jinna

AU - Yoon, Sun Och

AU - Kim, Hye Ryun

AU - Cho, Byoung Chul

N1 - Funding Information: This work was supported by a grant from the National Research Foundation (NRF), Republic of Korea (NRF- 2016M3C9A4922809 to Hye Ryun Kim). Publisher Copyright: © 2017 Wiley Periodicals, Inc.

PY - 2018/1

Y1 - 2018/1

N2 - Background: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m2) on days 1 and 8 plus cisplatin (80 mg/m2) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate. Progression-free survival (PFS), overall survival (OS), and adverse events were also assessed. Results: Between September 2008 and November 2014, 40 patients with recurrent and/or metastatic salivary gland cancer received vinorelbine plus cisplatin chemotherapy. The objective response rate was 35.0%, including 1 complete response. Median PFS and OS rates were 6.3 months and 16.9 months, respectively. No treatment-related deaths occurred. Conclusion: Administering vinorelbine plus cisplatin chemotherapy to patients with recurrent and/or metastatic salivary gland cancers is safe and effective.

AB - Background: The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods: In this single-arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m2) on days 1 and 8 plus cisplatin (80 mg/m2) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate. Progression-free survival (PFS), overall survival (OS), and adverse events were also assessed. Results: Between September 2008 and November 2014, 40 patients with recurrent and/or metastatic salivary gland cancer received vinorelbine plus cisplatin chemotherapy. The objective response rate was 35.0%, including 1 complete response. Median PFS and OS rates were 6.3 months and 16.9 months, respectively. No treatment-related deaths occurred. Conclusion: Administering vinorelbine plus cisplatin chemotherapy to patients with recurrent and/or metastatic salivary gland cancers is safe and effective.

UR - http://www.scopus.com/inward/record.url?scp=85038233746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038233746&partnerID=8YFLogxK

U2 - 10.1002/hed.24933

DO - 10.1002/hed.24933

M3 - Article

C2 - 29044862

AN - SCOPUS:85038233746

SN - 1043-3074

VL - 40

SP - 55

EP - 62

JO - Head and Neck

JF - Head and Neck

IS - 1

ER -

Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this